Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/58296
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study |
Author: | van Leeuwen, M. Webster, A. McCredie, M. Stewart, J. McDonald, S. Amin, J. Kaldor, J. Chapman, J. Vajdic, C. Grulich, A. |
Citation: | BMJ: British Medical Journal, 2010; 340(7774):C570-1-C570-6 |
Publisher: | British Medical Journal Publishing Group |
Issue Date: | 2010 |
ISSN: | 0959-535X 1756-1833 |
Statement of Responsibility: | Marina T van Leeuwen, Angela C Webster, Margaret R E McCredie, John H Stewart, Stephen P McDonald, Janaki Amin, John M Kaldor, Jeremy R Chapman, Claire M Vajdic and Andrew E Grulich |
Abstract: | Objective: To compare cancer incidence in kidney transplant recipients during periods of transplant function (and immunosuppression) and after transplant failure (when immunosuppression is ceased or reduced). Design, setting, and participants: Nationwide, population based retrospective cohort study of 8173 Australian kidney transplant recipients registered on the Australia and New Zealand Dialysis and Transplant Registry who first received a transplant during 1982-2003. Incident cancers were ascertained using linkage with national cancer registry records. Main outcome measures: Cancer-specific standardised incidence ratios for periods of transplant function and for dialysis after transplant failure. Incidence was compared between periods using multivariate incidence rate ratios adjusted for current age, sex, and duration of transplantation. Results: All cases of Kaposi’s sarcoma occurred during transplant function. Standardised incidence ratios were significantly elevated during transplant function, but not during dialysis after transplant failure, for non-Hodgkin’s lymphoma, lip cancer, and melanoma. For each of these cancers, incidence was significantly lower during dialysis after transplant failure in multivariate analysis (incidence rate ratios 0.20 (95% CI 0.06 to 0.65) for non-Hodgkin’s lymphoma, 0.04 (0.01 to 0.31) for lip cancer, and 0.16 (0.04 to 0.64) for melanoma). In contrast, standardised incidence ratios during dialysis after transplant failure remained significantly elevated for leukaemia and lung cancer, and cancers related to end stage kidney disease (kidney, urinary tract, and thyroid cancers), with thyroid cancer incidence significantly higher during dialysis after transplant failure (incidence rate ratio 6.77 (2.64 to 17.39)). There was no significant difference in incidence by transplant function for other cancers. Conclusions: The effect of immunosuppression on cancer risk is rapidly reversible for some, but not all, cancer types. Risk reversal was mainly observed for cancers with a confirmed infectious cause. Risk of other cancers,especially those related to end stage kidney disease,remained significantly increased after reduction of immunosuppression. |
Keywords: | Humans Neoplasms Kidney Failure, Chronic Renal Dialysis Kidney Transplantation Incidence Risk Factors Retrospective Studies Graft Rejection Adult Australia Female Male Infections Immunosuppression Therapy |
Rights: | © van Leeuwen et al 2010. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. |
DOI: | 10.1136/bmj.c570 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/401131 http://purl.org/au-research/grants/nhmrc/510346 |
Published version: | http://dx.doi.org/10.1136/bmj.c570 |
Appears in Collections: | Aurora harvest 5 Medicine publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_58296.pdf | Published version | 139.62 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.